Top

Published in:

01-07-2008 | News item

Update on intranasal desmopressin

Published in: Reactions Weekly | Issue 1/2008

Excerpt

Ferring Pharmaceuticals has issued a Health Canada-endorsed 'Dear Health Care Professional' letter advising that, because of increased risk of hyponatraemia, all intranasal desmopressin formulations, including DDAVP spray and DDAVP Rhinyle Solution, are no longer indicated for the treatment of primary nocturnal enuresis (PNE). …

Ferring Pharmaceuticals.New safety information regarding the antidiuretic drug desmopressin (DDAVP Rm) spray and DDAVP Rm) Rhinyle solution. Internet Document: [4 pages], 15 Jul 2008. Available from: URL: http://www.hc-sc.g.cca

Title: Update on intranasal desmopressin
Publication date: 01-07-2008
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2008
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-200812120-00007

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Update on intranasal desmopressin

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2008

Epirubicin/ifosfamide

Pyrazinamide increases the risk of liver injury

Paclitaxel

Vincristine

Propranolol/venlafaxine interaction

Metformin